Sep 08, 2022 / 01:45PM GMT
Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
All right. Good morning, everyone. I'm Larry Biegelsen, in the medical device analyst at Wells Fargo. It's my pleasure to host this session with Edwards Lifesciences.
With us, we have Scott Ullem, the CFO; and Mark Wilterding, Head of Investor Relations. In terms of format, it's going to be a fireside chat. If anyone has a question they want me to ask or they want to ask, just raise your hand and we'll call on you. So Scott, thanks so much for being here.
Scott B. Ullem - Edwards Lifesciences Corporation - Corporate VP & CFO
It's our pleasure. Thanks for having us.
Questions and Answers:
Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research AnalystSo Scott, we're starting all these fireside chats with the macro environment, no surprise. Edwards was impacted in the second quarter, right, some macro challenges like contrast
Trustpilot
